Trial Profile
A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Acronyms ClearMEMory
- 18 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 18 May 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.
- 10 May 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.